Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Blood (2008) 112 (10): 3965–3973.

https://doi.org/10.1182/blood-2008-06-161737

Published: 2008

Includes: Supplemental data

Journal Articles

Increasing Frequency and Marked Stability of Complete Molecular Response Is Observed in Imatinib-Treated CML Patients with Long-Term Follow Up.

Susan Branford, John Francis Seymour, Andrew Grigg, Chris Arthur, Kevin Lynch, Timothy Hughes

Blood (2006) 108 (11): 430.

https://doi.org/10.1182/blood.V108.11.430.430

Published: 2006

Journal Articles

Significant Reduction of BCR-ABL Transcripts after Switching to Imatinib Therapy in Patients with CML and Complete or Near-Complete Cytogenetic Responses to Interferon-Alpha (IFN).

Susan Branford, Timothy Hughes, Steven Stylian, Anthony P. Schwarer, Chris Arthur, Robin Filshie, Susan Moreton, Robyn Rodwell, Nancy Guzzo-Pernell, Deb Taylor, Jenny Larson, Rachel Koelmayer, Alvin Milner, Kevin Lynch, Kerry McDonald Taylor

Blood (2006) 108 (11): 2142.

https://doi.org/10.1182/blood.V108.11.2142.2142

Published: 2006

Journal Articles

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

Timothy P. Hughes, Susan Branford, John Reynolds, Rachel Koelmeyer, John Seymour, Kerry Taylor, Nancy Guzzo-Pernell, Robin Filshie, Chris Arthur, Anthony Schwarer, Mark Hertzberg, Michael Copeman, Kevin Lynch, Andrew Grigg

Blood (2005) 106 (11): 164.

https://doi.org/10.1182/blood.V106.11.164.164

Published: 2005

Journal Articles

An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation.

Andrew Spencer, DM, Andrew Grigg, MBBS, John Catalano, MBBS, Michael Leahy, MBBS, Craig Underhill, MBBS, Chris Arthur, MBBS, James DRozario, MBBS, Ray Lowenthal, DM, Kerry Taylor, MBBS

Blood (2005) 106 (11): 3336.

https://doi.org/10.1182/blood.V106.11.3336.3336

Published: 2005

Journal Articles

Phase II Pilot Study of Imatinib Mesylate Combined with Induction Chemotherapy in Blast-Phase CML and Ph+ ALL.

Jason Lickliter, MD, Chris Arthur, MD, James D’Rozario, MD, Chi-hung Hui, MD, Jeffrey Szer, MD, Kerry Taylor, MD, Anne-Marie Watson, MD, Jennifer McCarron, BSc, Kevin Lynch, MD, Ken Bradstock, MD, PhD

Blood (2004) 104 (11): 4682.

https://doi.org/10.1182/blood.V104.11.4682.4682

Published: 2004

Journal Articles

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Susan Branford, Zbigniew Rudzki, Ian Parkinson, Andrew Grigg, Kerry Taylor, John F. Seymour, Simon Durrant, Peter Browett, Anthony P. Schwarer, Chris Arthur, John Catalano, Michael F. Leahy, Robin Filshie, Kenneth Bradstock, Richard Herrmann, David Joske, Kevin Lynch, Tim Hughes

Blood (2004) 104 (9): 2926–2932.

https://doi.org/10.1182/blood-2004-03-1134

Published: 2004

Journal Articles

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Susan Branford, Zbigniew Rudzki, Sonya Walsh, Ian Parkinson, Andrew Grigg, Jeff Szer, Kerry Taylor, Richard Herrmann, John F. Seymour, Chris Arthur, David Joske, Kevin Lynch, Tim Hughes

Blood (2003) 102 (1): 276–283.

https://doi.org/10.1182/blood-2002-09-2896

Published: 2003

Journal Articles

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Susan Branford, Zbigniew Rudzki, Sonya Walsh, Andrew Grigg, Chris Arthur, Kerry Taylor, Richard Herrmann, Kevin P. Lynch, Timothy P. Hughes

Blood (2002) 99 (9): 3472–3475.

https://doi.org/10.1182/blood.V99.9.3472

Published: 2002

NARROW

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Increasing Frequency and Marked Stability of Complete Molecular Response Is Observed in Imatinib-Treated CML Patients with Long-Term Follow Up.

Significant Reduction of BCR-ABL Transcripts after Switching to Imatinib Therapy in Patients with CML and Complete or Near-Complete Cytogenetic Responses to Interferon-Alpha (IFN).

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation.

Phase II Pilot Study of Imatinib Mesylate Combined with Induction Chemotherapy in Blast-Phase CML and Ph+ ALL.

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only